---
schema_version: "secwatch.filing_event.v1"
accession: "0001804220-23-000021"
form_type: "8-K"
ticker: "REGN"
cik: "0000872589"
company_name: "REGENERON PHARMACEUTICALS, INC."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T10:31:20.461142+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Regeneron Q2 revenues up 11% to $3.16B; EPS $8.50 GAAP/$10.24 non-GAAP

## Summary
- Q2 2023 total revenues $3.158B (+11% YoY); GAAP diluted EPS $8.50 (up 14%); non-GAAP diluted EPS $10.24 (up 5%).
- Dupixent global net sales (Sanofi) rose 33% to $2.79B; EYLEA US net sales fell 7% to $1.50B on lower pricing/competition.
- FDA issued CRL for aflibercept 8 mg due to contract manufacturer issues; expects FDA action on BLA in Q3 2023.
- Repurchased $723M in shares during Q2; $2.3B remained under buyback program as of June 30, 2023.
- Updated 2023 guidance: GAAP R&D $4.315-4.455B; non-GAAP R&D $3.825-3.925B; SG&A and gross margin ranges unchanged.

## SEC filing metadata
- accession: 0001804220-23-000021
- form_type: 8-K
- ticker: REGN
- cik: 0000872589
- company_name: REGENERON PHARMACEUTICALS, INC.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872589/000180422023000021/0001804220-23-000021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872589/000180422023000021/regn-20230803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001804220-23-000021
- JSON: https://secwatch.observer/filing/0001804220-23-000021.json
- Plain text: https://secwatch.observer/filing/0001804220-23-000021.txt

## Key facts
- Earnings Releases
  REGENERON PHARMACEUTICALS, INC. reported the quarter ended June 30, 2023 results: revenue $3.16 billion, EPS $8.50.
  - Period: the quarter ended June 30, 2023
  - Revenue: $3.16 billion
  - EPS: $8.50
  - Result: reported results
  source text: EXHIBIT 99.1 Document Exhibit 99.1 Press Release Regeneron Reports Second Quarter 2023 Financial and Operating Results • Second quarter 2023 revenues increased 11% to $3.16 billion versus second quarter 2022 • Second quarter 2023 Dupixent ® global net sales (recorded by Sanofi) increased 33% to $2.79 billion versus second quarter 2022 • Second quarter 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/872589/000180422023000021/0001804220-23-000021-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.